Kezar Life Sciences, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
Mailing Address 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
Phone 650-822-5600
Fiscal Year End 1231
EIN 473366145
Financial Overview
FY2025
-$56.03M
Net Income
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 10-K Annual financial report | March 27, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 9, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| 8-K Current report of material events | November 12, 2025 | View on SEC |
| 8-K Current report of material events | November 7, 2025 | View on SEC |
| 8-K Current report of material events | October 22, 2025 | View on SEC |
Annual Reports
10-K March 27, 2026
- Exploring strategic alternatives including potential sale, merger, or licensing
- Cash runway extended into 2027 with $109.5 million in reserves
Material Events
8-K Acquisition March 30, 2026
High Impact
- Acquisition of Kezar Life Sciences by Aurinia Pharmaceuticals
- Guaranteed cash payment of $6.955 per share for KZR shareholders
8-K Strategy Change March 12, 2026
High Impact
- Kezar Life Sciences divests its Sec61-based discovery program, including KZR-261, to Enodia Therapeutics SAS.
- The transaction includes an immediate $1 million cash infusion and potential future payments of up to $127 million in milestones plus tiered royalties.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.